Yuan Jia HU 胡元佳

• Generating natural product-like libraries for drug discovery with autoencoder based recurrent neural networks, State Key Laboratory of Quality Research in Chinese Medicine (UM), 2022, PI.
• Data mining and molecular generation of small molecule inhibitor patent compounds, UM–Dr. Stanley Ho Medical Development Foundation, 2022, PI.
• HER2 target technology scan and drug launch trend analysis, Enterprise Project, 2021-2023, PI.
• Research on advanced development of Yuanhu Zhitong Koufuye and Gan Wei Kang Pian, Enterprise Project, 2021-2023, PI.
• Medical technological scanning and policy dynamics analysis, Enterprise Project, 2021-2024, PI.
• A network pharmacology-based study on the quality control markers of antithrombotic herbs: Using Salvia miltiorrhiza and its herbal pairs as examples, University of Macau, 2020-2021, PI.
• Research on access and regulation system of traditional Chinese medicine in Cape Verde, Enterprise Project, 2020-2021, PI.
• The development of new anti-ischemic indication of Liujing Toutong Pian, Science and Technology Bureau of Shanxi, 2019-2022, Co-I.
• Simulation of regional knowledge creation in EU and China, Austrian Science Fund, 2019-2022, Co-I.
• Screening of antithrombotic natural products by network analysis and bio-affinity extraction, University of Macau, 2017-2019, PI.
• Research about material basis and combination principles of Zengye-Tang for the treatment of diabetes based on complex network system of “ingredient-target-effect”, The National Natural Science Foundation of China, 2016-2019, Co-I.
• The cooperative construction of a big data platform for Chinese Medicine, Enterprise Project, 2017-2019, Co-I.
• Research on material basis and combination principles of Shengmai-San similar formulas for the treatment of coronary heart disease based on complex networks of “ingredient-target-effect”, The Science and Technology Development Fund of Macao, 2016-2018, PI.
• Narrowing the gap between bench and bedside: Reexamining China’s pharmaceutical innovation, University of Macau, 2015-2018, PI.
• Studies of active ingredients from anti-Alzheimer’s Chinese herbal formulae by network analysis and pharmacological examinations, University of Macau, 2015-2018, PI.
• Finding communities in Chinese drug innovation networks: Characteristics, determinants and strategies, University of Macau, 2012-2015, PI.
• Global Pharmaceutical Innovation Networks: A Quantitative Study Based on U.S. Drug Patents, University of Macau, 2011-2012, PI.
• Innovation and economic value of pharmaceuticals: evidence from patent statistics, University of Macau, 2011-2011, PI.

• Over 200 peer-reviewed publications (* corresponding author)
• For more details, please see the linkage,
  https://scholar.google.com/citations?user=Xh2eRIMAAAAJ&hl=en.

Journal Articles

1. X.J. Kong, K. M. Liu, H. L. Zuo, H. D. Huang, Y.J. Hu*, The changing global landscape in the development of artemisinin-based treatments: A clinical trial perspective, The American Journal of Chinese Medicine, 1-16, 2022.
2. D.Y. Zhang, R.Q. Peng, X. Wang, H.L. Zuo, L.Y. Lyu, F.Q. Yang*, Y.J. Hu*, A network pharmacology-based study on the quality control markers of antithrombotic herbs: Using Salvia miltiorrhiza – Ligusticum chuanxiong as an example, Journal of Ethnopharmacology, 292:115197, 2022.
3. Y.Feng, K.M. Liu, L.Y. Lyu, G.J. Sun, Y.J. Hu*, The financial impact of patents on SMEs in China: Empirical evidence from pharmaceutical sector, Science, Technology and Society, 27(1):46-65, 2022.
4. J.Yang, L. Hou, K.M. Liu, W.B. He, Y. Cai, F.Q. Yang*, Y.J. Hu*, ChemGenerator: a web server for generating potential ligands for specific targets. Briefings in Bioinformatics (IF=11.622), DOI: 10.1093/bib/bbaa407, 2021.
   ChemGenerator (tcmobile.org)
5. T.T. Tao, R. Shao*, Y.J. Hu*, The effects of childhood circumstances on health in middle and later life: Evidence from China,Frontiers in Public Health, 54, 2021.
6. K.M. Liu, Z.X. Gu, M.S. Islam, T. Scherngell, X.J. Kong, J. Zhao, X. Chen, Y.J. Hu*, Global landscape of patents related to human coronaviruses, International Journal of Biological Sciences, 17(6): 1588, 2021.
7. H.L. Zuo, Q.R. Zhang, C. Chen, F.Q. Yang, H. Yu*, Y.J. Hu*, Molecular evidence of herbal formula: a network‐based analysis of Si‐Wu decoction, Phytochemical Analysis, 32(2): 198-205, 2021.
8. L.Y. Lyu, Y. Feng, X. Chen, Y.J. Hu*, The global chimeric antigen receptor T (CAR-T) cell therapy patent landscape. Nature Biotechnology (IF=54.908), 38:1387-1394, https://rdcu.be/cbFlW, 2020.
9. H.L. Zuo, K.G. Linghu, Y.L. Wang, K.M. Liu, Y. Gao, H. Yu, F.Q. Yang*, Y.J. Hu*, Interactions of antithrombotic herbal medicines with Western cardiovascular drugs. Pharmacological Research, 159:104963, 2020.
10. K.M. Liu, H.L. Zuo, G.G. Li, H. Yu, Y.J. Hu*, Global research on artemisinin and its derivatives: Perspectives from patents, Pharmacological Research, 159:105048, 2020.
11. R.L. Song, Y.J. Hu, Pharmaceutical patent term extension: Balancing innovation and imitation, China Reform, 3:21, 2020. (in Chinese)
    宋瑞霖, 胡元佳, 藥品專利期限補償：創新與仿製的平衡, 中國改革, 3:21, 2020.
12. Y.J. Hu, R.L. Song, Patent transformation: A key of Chinese medical innovation, China Reform, 5:61-63, 2020. (in Chinese)
    胡元佳, 宋瑞霖, 專利轉化：中國醫藥創新的關鍵, 中國改革, 5:61-63, 2020.
13. D.Y. Zhang, Y. Zhang, Y. Gao, X.Y. Chai, R.B. Pi, G. Chan*, Y.J. Hu*, Translating traditional herbal formulas into modern drugs: a network-based analysis of Xiaoyao decoction, Chinese Medicine, 15(1): 1-11, 2020.
14. S.Y. Hu, H.L. Zuo, J. Qi, Y.J. Hu*, Yu Boyang*, Analysis of effects of Schisandra in the treatment of myocardial infarction based on three-mode gene ontology network, Frontiers in Pharmacology, 10: 232, 2019.
15. G.Y. Li, Y. Zhou, D.M.Y. Sze, C. Liu, Q.R. Zhang, Z.H. Wang, H. Yu, G. Chan, Z.D. Wu, S.B. Su*, Y.J. Hu*, Active ingredients and action mechanisms of Yi Guan Jian Decoction in chronic hepatitis B patients with liver fibrosis, Evidence-Based Complementary and Alternative Medicine, 2408126, 2019.
16. Z.H. Wang, H.H. Lin, K.G. Linghu, R.Y. Huang, G.Y. Li, H.L. Zuo, H. Yu, G. Chan, Y.J. Hu*, Novel compound-target interactions prediction for the herbal formula Hua-Yu-Qiang-Shen-Tong-Bi-Fang, Chemical and Pharmaceutical Bulletin, 67(8): 778-785, 2019.
17. F.B. Xia, F.G. Xu, H.X. Su, C.W. He, Y.J. Hu*, J.B. Wan*, Quantification of phospholipid fatty acids by chemical isotope labeling coupled with atmospheric pressure gas chromatography quadrupole-time-of-flight mass spectrometry (APGC/Q-TOF MS), Analytica Chimica Acta, 1082: 86-97, 2019.
18. Q.R. Zhang, Z.F. Zhong, W. Sang, W. Xiong, H.X. Tao, G.D. Zhao, Z.X. Li, Q.S. Ma, K.W.T. Anfernee, Y.J. Hu*, H. Yu*, Y.T. Wang, Comparative comprehension on the anti-rheumatic Chinese herbal medicine Siegesbeckiae Herba: combined computational predictions and experimental investigations, Journal of Ethnopharmacology, 228: 200-209, 2019.
19. H.L. Zuo, F.Q. Yang*, Y.J. Hu*, Investigation of possible herb-drug interactions for the treatment of cardiovascular diseases, Seminars in Thrombosis and Hemostasis, 45(05): 548-551, 2019.
20. J.W. Qv, J.H. Lu, Y.J. Hu*, Research and development of anti-Parkinson’s drugs: an analysis from the perspective of technology flows measured by patent citations. Expert Opinion on Therapeutic Patents, 29(2): 127-135, 2019.
21. Z.F. Zhong, Q.R. Zhang, H.X. Tao, W. Sang, L. Cui, W.N. Qiang, W.S. Cheang, Y.J. Hu*, H. Yu*, Y.T. Wang, Anti-inflammatory activities of Sigesbeckia glabrescens Makino: combined in vitro and in silico investigations, Chinese Medicine, 14: 35, 2019.
22. R. Jiang, Y.Y. Sun, C.O.L. Ung, X.Y. Dong, X.J. Kong, Y.J. Hu*, R. Shao*, Research and development of mAb drugs in China: a look from policy perspectives, Human Vaccines & Immunotherapeutics, 15(11): 2695-2705,2019.
23. J.Z. Yan, H. H Lin, D. Zhao, Y.J. Hu*, R. Shao*, China’s new policy for healthcare cost-control based on global budget: a survey of 110 clinicians in hospitals, BMC Health Services Research, 19(1): 84, 2019.
24. S. Li, Y.J. Hu, Network pharmacology: An approach to the analysis of complex systems underlying traditional Chinese medicine, World Journal of Traditional Chinese Medicine, 4(4): 135, 2018.
25. H.L. Zuo, Q.R. Zhang, S.B. Su, Q.L. Chen, F.Q. Yang*, Y.J. Hu*, A network pharmacology-based approach to analyse potential targets of traditional herbal formulas: An example of Yu Ping Feng decoction, Scientific Reports, 8: 11418, 2018.
26. H.H. Lin, D.F. Ouyang, Y.J. Hu*, Intelligent Classifier: A Tool to Impel Drug Technology Transfer from Academia to Industry, Journal of Pharmaceutical Innovation, 1-8, 2018.
27. K.M. Liu, H.H. Lin, R.B. Pi, S.H. Mak, Y.F. Han, Y.J. Hu*, Research and development of anti-Alzheimer’s disease drugs: an update from the perspective of technology flows, Expert Opinion on Therapeutic Patents, 28(4): 341-350, 2018.
28. X.J. Kong, Q.R. Zhang, Y.F. Lai, H. Hu, X. Chen, Y.J. Hu*, Global patent landscape of programmed cell death 1: implications of the rapid expansion. Expert Opinion on Therapeutic Patents, 28(1): 69-80, 2018.
29. H.H. Lin, L.L. Zhang, Y. Ru, J.J. Lu*, Y.J. Hu*, Network analysis of drug-target interactions: A study on FDA-approved New Molecular Entities between 2000 to 2015, Scientific Reports, 7: 12230, 2017.
30. X.J. Kong, J.B. Wan, H. Hu, S.B. Su, Y.J. Hu*, Evolving patterns in a collaboration network of global R&D on monoclonal antibodies, MAbs, 9(7): 1041-1051, 2017.
31. Q.R. Zhang, H. Yu, J. Qi, D.S. Tang, X.J. Chen, J.B. Wan, P. Li, H. Hu, Y.T. Wang, Y.J. Hu*, Natural formulas and the nature of formulas: Exploring potential therapeutic targets based on traditional Chinese herbal formulas, Plos One, 12(2): 1-14, 2017.
32. Q.R. Zhang, X.J. Kong, H.Y. Xu, Y.T. Wang, Y.J. Hu*, Progress of studies on traditional Chinese medicine-based on complex network analysis, World Journal of Traditional Chinese Medicine, 3: 1-10, 2017.
33. J.Y. Ni, J.R. Zhao, C.O.L Ung, Y.J. Hu*, H. Hu, Y.T. Wang, Obstacles and opportunities in Chinese pharmaceutical innovation, Globalization and Health, 13(1): 1-9, 2017.
34. J.L. Deng, K.W. Sitou, Y.P. Zhang, R.Yan, Y.J. Hu*, Analyzing the Chinese landscape in anti-diabetic drug research: leading knowledge production institutions and thematic communities, Chinese Medicine, 11: 13, 2016.
35. J.Y. Ni, J. B. Wan, X.J. Kong, Y. Cai, F.Q. Yang, Y.T. Wang, Y.J. Hu*, Pharmaceutical technology licensing: An analysis in the field of cardiovascular disease, Journal of Pharmaceutical Innovation, 11(1): 34-45, 2016.
36. M. Zhang, X.J. Kong, J. Zheng, J.B. Wan, Y.T. Wang, Y.J. Hu*, R. Shao, Research and development of antibiotics: insights from patents and citation network, Expert Opinion on Therapeutic Patents, 26: 617-627, 2016.
37. Ding, Q.R. Zhang, C.O.L. Ung, Y.T. Wang, Y.F. Han, Y.J. Hu*, J. Qi, An analysis of chemical ingredients network of Chinese herbal formulae for the treatment of coronary heart disease, Plos One, 10(2): e0116441, 2015.
38. X.J. Kong, Y.J. Hu*, Z.F. Cai, F.Q. Yang, Q.R. Zhang, Dendritic-cell-based technology landscape: Insights from patents and citation networks, Human Vaccines & Immunotherapeutics, 11(3):682-688, 2015.
39. X.J. Kong, W.X. Zhou, J.B. Wan, Q.R. Zhang, J.Y. Ni, Y.J. Hu*, An integrative thrombosis network: Visualization and topological analysis. Evidence-Based Complementary and Alternative Medicine, 2: 265303, 2015.
40. H. You., M. Barber, T. Scherngell, J.Y. Ni, Y.J. Hu*, China’s landscape in oncology drug research: Perspectives from research collaboration networks. Chinese Journal of Cancer Research, 27(2):138-147, 2015.
41. Y.J. Hu, T. Scherngell, L. Qiu, Y.T. Wang, R&D internationalisation patterns in the global pharmaceutical industry: Evidence from a network analytic perspective. Technology Analysis & Strategic Management, 27(5):532-549, 2015.
42. J.Y. Ni, R. Shao, C.O.L. Ung, Y.T. Wang, Y.J Hu*, Y. Cai, Valuation of pharmaceutical patents: A comprehensive analytical framework based on technological, commercial, and legal factors. Journal of Pharmaceutical Innovation, 10(3):281-285, 2015.
43. X.M. Geng, X.J. Kong, H. Hu, J.Y. Chen, F.Q. Yang, H.Y. Liang, X. Chen, Y.J. Hu*, Research and development of therapeutic mAbs: An analysis based on pipeline projects, Human Vaccines & Immunotherapeutics, 11(12):2769-2776, 2015.
44. J.C. Xu, X. J. Kong, L. Qiu, X. M. Geng, Y.J. Hu*, Y.T. Wang, Research and development of anti-Alzheimer’s drugs: An analysis based on technology flows measured by patent citations, Expert Opinion on Therapeutic Patents, 7: 1-10, 2014.
45. T. Scherngell, M. Borowiecki, Y.J. Hu*, Effects of knowledge capital on total factor productivity in China: a spatial econometric perspective, China Economic Review, 29: 82-94, 2014.
46. Y.J. Hu*, T. Scherngell, S. N. Man, Y.T. Wang, Is the United States still dominant in the global pharmaceutical innovation network? Plos One, 8(11), e77247, 2013.
47. Y. Guo, Y.J. Hu*, Y.T. Wang, Patent indicators: A window on pharmaceutical market value, Expert Opinion on Therapeutic Patents, 6: 1-6, 2013.
48. J.Y. Ni, J.C. Xu, Y.J. Hu*, L. Su, Y.T. Wang, Cross-regional pharmaceutical technology transfer in China: Patterns and proposed investment strategies, Therapeutic Innovation & Regulatory Science, 8: 1-10, 2013.
49. J.J. Lu, W. Pan, Y.J. Hu*, Y.T. Wang*, Multi-target drugs: The trend of drug research and development, Plos One, 7(6): 1-6, 2012. (ESI Highly Cited Paper)
50. T. Scherngell and Y.J. Hu, Collaborative knowledge production in China: Regional evidence from a gravity model approach, Regional Studies, 45: 755-772, 2011.
51. Y.J. Hu, Y. Bian, Y.T. Wang, Opening the “black box” of pharmaceutical patent value: An empirical analysis, Drug Information Journal, 42(6): 561-568, 2008.
52. Y.J. Hu, C. O. L. Ung, Y. Bian, Y.T. Wang, The Chinese pharmaceutical market: Dynamics and a proposed investment strategy, Journal of Medical Marketing, 7(1): 18-24, 2007. (Best Paper Award)
53. Y.J. Hu, F. Geng, Y. Bian, Y.T. Wang, The Chinese pharmaceutical market: Perspectives of the health consumer, Journal of Medical Marketing, 7(4): 295-300, 2007.
54. Y.J. Hu, Y. Bian, Y.T. Wang, Secrets of blockbuster drugs: Data mining for oppositions against patents, Drug Information Journal, 41(3): 425, 2007.
    
    International Standard
55. Network Pharmacology Evaluation Methodology Guidance. 網絡藥理學評價方法指南. International Standard of WFCMS
    
    
    Book Chapters
56. S.B. Su, Y.J. Hu*, H.L. Zuo, Case Study of Network Pharmacology and Modernization of Traditional Chinese Medicine, in Network Pharmacology. Springer, Singapore, 2021.
57. I.L. Chio, K.M. Liu, G. Chan*, Y.J. Hu*, Research and development of anti-cancer monoclonal antibodies in china: an analysis based on patents, in Biotechnology in Hong Kong IV, United States-China Intellectual Property Institute, Hong Kong, 2020.
58. Y.T. Wang, Y.J. Hu, A.W.K. Chan, Innovation Value Chain of Chinese Pharmaceuticals, United States-China Intellectual Property Institute, New York, 2017.
59. H.H Lin, P.P Li, X.J. Kong, J. Cai, S.B. Su, Y.J. Hu*, An analysis of evolutionary conservation based on genomic orthology and protein-protein interaction networks, in Biotechnology in Hong Kong III, United States-China Intellectual Property Institute, Hong Kong, 2017.
60. K.W. Sitou, J.B. Wan, M.S.H. Mak, Y.F. Han, Y.J. Hu*, Monitoring drug research on clinical neurology in China: an analysis of institutional leaders and community themes, in Innovation Value Chain of Chinese Pharmaceuticals, United States-China Intellectual Property Institute, New York, 2017, Chapter 3.
61. X.J. Kong, H Lu, Q.R. Zhang, H.L. Zuo, Y.J. Hu*, A.W. Chan*, Global landscape of research and development on antibiotics, in Innovation Value Chain of Chinese Pharmaceuticals, United States-China Intellectual Property Institute, New York, 2017, Chapter 5.
62. X.J. Kong, H.Y. Liang, Q.W. Yuan, Y.J. Hu*, Entry inhibitors for AIDS therapy: a review of research and development projects, in Innovation Value Chain of Chinese Pharmaceuticals, United States-China Intellectual Property Institute, New York, 2017, Chapter 6.
63. T.H. Yin, X.J. Kong, Y.T. Wang, X. Chen, Y.J. Hu*, R. Shao*, Collaboration networks for R&D of monoclonal antibodies: an analysis based on pipeline projects, in Innovation Value Chain of Chinese Pharmaceuticals, United States-China Intellectual Property Institute, New York, 2017, Chapter 7.
64. H.H. Lin, S.Q. Tian, M.S.H. Mak, Y.F. Han, Y.J. Hu*, An analysis of technology flows of antidepressants based on patent citation network, in Innovation Value Chain of Chinese Pharmaceuticals, United States-China Intellectual Property Institute, New York, 2017, Chapter 9.
65. J.Y. Ni, R. Shao, C.O.L. Ung, Y.T. Wang, Y.J. Hu*, Y. Cai, Pharmaceutical patent valuation based on empirical models, in Innovation Value Chain of Chinese Pharmaceuticals, United States-China Intellectual Property Institute, New York, 2017, Chapter 10.
66. J.Y. Ni, Y.J. Hu*, J.B. Wan, T. Scherngell, F. Kwan, Cross-regional pharmaceutical technology transfer in china: an empirical study based on spatial interaction model, in Innovation Value Chain of Chinese Pharmaceuticals, United States-China Intellectual Property Institute, New York, 2017, Chapter 11.
67. Wan, J.R. Zhao, B.Y. Zhang, D.N. Yao, Y.J. Hu*, Changing pharmaceutical registration rules in china: latest updates and potential impacts, in Innovation Value Chain of Chinese Pharmaceuticals, United States-China Intellectual Property Institute, New York, 2017, Chapter 12.
68. P.P. Li, H.H. Lin, Y.J. Hu*, Pharmaceutical innovation network: global patterns and the role of China. Innovation Value Chain of Chinese Pharmaceuticals, in Innovation Value Chain of Chinese Pharmaceuticals, United States-China Intellectual Property Institute, New York, 2017, Chapter 13.
69. H.W. Kuok, X.J. Kong, Y.J. Hu*, Y.T. Wang, Discovering miRNAs in cancer: China’s landscape and the role of Hong Kong, in Biotechnology in Hong Kong, United States-China Intellectual Property Institute, Hong Kong, 2015, Chapter 2.
    Conference Proceedings
70. Li, F., J. Hu. (31/01/2021). The global patent landscape of small interference RNA delivery technology. AEIC Series Conferences. Xiamen, China.
71. Liu, K.M., Chan, G., J. Hu. (10/05/2018). The influence of communication method among clinic doctors on satisfaction of patients in Traditional Chinese Medicine hospitals in Beijing. http://www.ichsm.org. Tsukuba, Japan.
72. Yuan, Q. W., J. Hu., Hu, H., Ging, C., Ouyang, D. (25/04/2018). Translational efficiency and clinical success rate of key drug delivery technologies: from bench to bedside. Translational efficiency and clinical success rate of key drug delivery technologies: from bench to bedside. Bali, Indonesia.
73. Geng, X. M., Kong, X. J., Chen, Q. L., Su, S. B., J. Hu. (15/03/2017). Analysis of miRNA functional synergistic network in breast cancer. Analysis of miRNA functional synergistic network in breast cancer. Prague, Czech Republic.
74. Zhang, Q. R., Wang, Y. T., J. Hu., Yu, H. (22/11/2016). Comparative characterization for three plant origins of Siegesbeckiae Herba: a view from chemometrics, molecular docking and complex network analysis approaches. IX International Symposium on Natural Products Chemistry and Applications. Chile.
75. Borowiecki, M.B., Scherngell, T.S., J. Hu. (09/2013). Effects of knowledge capital on total factor productivity in China: A spatial econometric perspective. 53rd ERSA Congress. Palermo, Italy.

1. 專利大數據分析及其在生物醫藥研發中的應用，西安交通大學抗疫雲課堂，西安交通大學，主講嘉賓，2022。
2. 一種突破性癌症療法的全球專利解碼以及對中國藥物創新的啟發，澳大學人研究講壇，澳門大學，主講嘉賓，澳門，2021。
3. “後疫情時代”的中國醫藥創新：基於專利轉化的分析，第五屆中國醫藥創新與投資大會，中國醫藥創新促進會，主講嘉賓，蘇州，2020。
4. 生物醫藥專利——大數據資源及產業應用，第二十屆中國生物製品年會，中國疫苗行業協會，主講嘉賓，珠海，2020。
5. 中藥網絡與網絡中藥，世界中醫藥學會聯合會網絡藥理專業委員會第四屆學術年會，世界中醫藥學會聯合會網絡藥理學專業委員會，主講嘉賓，福州，2019。
6. 運用人工智慧促進大學技術轉移，內地與香港、澳門特別行政區知識產權研討會，國家知識產權局/香港知識產權署/澳門經濟局，主講嘉賓，敦煌，2018。
7. Pre-workshop: Big data analytics in patents. The 9th IP Seminar: Global Competitiveness and Business Value through Innovation. The Chinese University of Hong Kong. Invited Speaker and Chair, Hong Kong, 2017.
8. 世界中醫藥學會聯合會網絡藥理學國際論壇暨專業委員會第二屆學術年會，世界中醫藥學會聯合會網絡藥理學專業委員會，主持人，中國合肥，2017。
9. 國家知識產權局專利局處級幹部研修班，中國青年政治學院，研修班授課教師，珠海，2017。
10. 首屆知識產權運營七弦琴高峰論壇，橫琴國際知識產權交易中心，特邀報告，中國珠海，2016。
11. Cross-regional pharmaceutical development in China: An empirical study based on technology transfer. The 14^th Annual Meeting of CGCM. Consortium for Globalization of Chinese Medicine, Canada, 2015.
12. Network-based identification of therapeutic targets from traditional herbal formulae. The 7^th AASP Conference. Asian Association of Schools of Pharmacy, Taipei, Taiwan, 2015.
13. Patent: A powerful indicator to measure drug innovation. Mainland, Hong Kong SAR and Macao SAR intellectual property symposium. State Intellectual Property Office, Intellectual Property Department of Hong Kong, and Economic Services of Macao, Hong Kong, 2014.
14. Pharmaceutical patent valuation: Novel models and applications in industry. The 46^thS. DIA Annual Meeting. U.S. Drug Information Association, Washington, D.C. USA, 2010 (Session Chair and Conference Grant).
15. A look at China’s pharmaceutical market. A Workshop on New Paradigms in Life Sciences Marketing. European Business School INSEAD, Paris, France, 2007 (Conference Grant).
16. Secrets of blockbuster drugs: Data mining for oppositions against patents. The 43^rd S. DIA Annual Meeting. U.S. Drug Information Association, Atlanta, USA, 2007 (Conference Grant).

1. Integrated Innovation and International Expansion of Frontier Technologies for Chinese Medicine Quality, First Prize of International Award for Contribution to Chinese Medicine, World Federation of Chinese Medicine Societies, 2020.
   中藥質量前沿技術的集成創新和國際拓展，中醫藥國際貢獻獎一等獎，世界中醫藥學會聯合會, 2020.
2. Macau Tertiary Education Professionals Training, Training Grant, Higher Education Bureau of Macau SAR, University of Cambridge, June 24 to July 3, 2019.
3. Patent valuation: Case study on pharmaceutical patents in China, Training Grant, WIPO-WTO Colloquium for IP Teachers, Geneva, June 13 to 24, 2016.
4. Pharmaceutical patent valuation, Scholarship of Eurasia Pacific Uninet (EPU), Austria, 2008-2009.
5. The First Award, 8^th Challenge Cup of China, 2003. 中國第八屆挑戰杯，一等獎，2003.

• 澳大學人剖析癌症療法全球專利格局（2021）
  https://www.gov.mo/zh-hant/news/384541/
• CAR-T專利格局：澳門大學胡元佳團隊利用專利大數據深入分析CAR-T全球研發生態（2021）
  https://3g.menet.com.cn/Article/Detial?aid=140837
• 上市公司路演專場｜15家上市藥企齊聚一堂 共譜創新藥產業全新篇章（2021）
  http://www.phirda.com/artilce_25506.html?cId=9
• 澳大調查：六成居民願種疫苗（2021）
  http://www.macaodaily.com/html/2021-06/22/content_1524891.htm
• 第37屆全國醫藥工業信息年會分論壇舉行 助力粵港澳中醫藥產業發展（2020）
  http://www.zhuhai.gov.cn/gkmlpt/content/2/2632/post_2632969.html#1638
• China drug in-licensing opportunities expected to swell as local pharma focus on R&D (2019)
  https://www.pharmaceutical-technology.com/comment/china-in-licensing-deals/
• 澳門高校教研人員赴海外瞭解各地高教情況；《澳門高等教育雜誌》（2019）
  https://es.dsedj.gov.mo/platform/shownews.asp?catid=1&newsid=137
  https://es.dsedj.gov.mo/hemagazine/index/index/book?id=29&lan=cn_mc（第23頁）
• 澳大學生獲全國藥學類論文一等獎（2017）
  https://www.gov.mo/zh-hans/news/148164/

1. Committee Member, The Talents Development Committee of the Macao SAR Government, 2022 – Present
2. Guest Researcher, Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, 2022 – Present
3. Member, Asia-Pacific Academy of Economics and Management, University of Macau, 2021 – Present
4. Executive Vice President, Consortium of ‘Belt and Road’ and Portuguese-Speaking Countries for Natural Medicine Innovation (Macao), 2021 – Present
5. Guest Editor, Journal of Ethnopharmacology, Network Pharmacology and AI, 2021-2022
6. Guest Editor, Frontiers in Pharmacology, Network Pharmacology and Traditional Medicine: Setting the New Standards by Combining In silico and Experimental Work, 2020-2021
7. Guest Editor, Frontiers in Pharmacology, Network Pharmacology and Traditional Medicine, 2019-2020
8. Director of Council, Macao Society for Medicinal Administration, 2020 – Present
9. Policy Expert, State Intellectual Property Operation Public Service Platform, Financial Innovation Pilot Platform, 2018 – Present
10. Arbitrator, Zhuhai Arbitration Commission, 2018 – Present
11. Project Researcher, The Research Center of National Drug Policy & Ecosystem, 2015 – Present
12. Deputy Secretary-General, Specialty Committee on Network Pharmacology, World Federation of Chinese Medicine Societies, 2015 – Present
13. Council Member, Specialty Committee of Information, World Federation of Chinese Medicine Societies, 2015 – Present
14. Founding Commissioner, Commission on Network Pharmacology, Chinese Pharmacological Society, 2014 – Present